Pulmonary arterial hypertension and statins: An update

Current Opinion in Cardiology

Volumn 26, Issue 4, 2011, Pages 322-326

  Katsiki, Niki ^a   Wierzbicki, Anthony S ^b   Mikhailidis, Dimitri P ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

endothelium; nitric oxide; pulmonary hypertension; statin; treatment

Indexed keywords

ATORVASTATIN; ENDOTHELIN RECEPTOR ANTAGONIST; FLUINDOSTATIN; PHOSPHODIESTERASE V INHIBITOR; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

HUMAN; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RESPIRATORY FUNCTION; REVIEW;

ANIMALS; BIOLOGICAL MARKERS; DISEASE MODELS, ANIMAL; DYSLIPIDEMIAS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION, PULMONARY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 79958806121     PISSN: 02684705     EISSN: 15317080     Source Type: Journal    
DOI: 10.1097/HCO.0b013e32834659bf     Document Type: Review

References (57)

1. Newman JH, Fanburg BL, Archer SL, et al. Pulmonary arterial hypertension: future directions - report of a National Heart, Lung and Blood Institute/Office of Rare Diseases workshop. Circulation 2004; 109:2947-2952.
2. Toshner M, Tajsic T, Morrell NW. Pulmonary hypertension: advances in pathogenesis and treatment. Br Med Bull 2010; 94:21-32. A useful and recent review.
3. Newman JH, Trembath RC, Morse JA, et al. Genetic basis of pulmonary arterial hypertension: current understanding and future directions. J Am Coll Cardiol 2004; 43:33S-39S.
4. Rhodes CJ, Davidson A, Gibbs JS, et al. Therapeutic targets in pulmonary arterial hypertension. Pharmacol Ther 2009; 121:69-88.
5. Gurbanov E, Shiliang X. The key role of apoptosis in the pathogenesis and treatment of pulmonary hypertension. Eur J Cardiothorac Surg 2006; 30:499-507. (Pubitemid 44189855)
6. Archer SL, Michelakis ED. An evidence-based approach to the management of pulmonary arterial hypertension. Curr Opin Cardiol 2006; 21:385-392.
7. Crosswhite P, Sun Z. Nitric oxide, oxidative stress and inflammation in pulmonary arterial hypertension. J Hypertens 2010; 28:201-212.
8. Bucher HC, Griffith LE, Guyatt GH. Systematic review on the risk and benefit of different cholesterol-lowering interventions. Arterioscler Thromb Vasc Biol 1999; 19:187-195. (Pubitemid 29072729)
9. Wierzbicki AS, Poston R, Ferro A. The lipid and nonlipid effects of statins. Pharmacol Ther 2003; 99:95-112.
10. Athyros VG, Kakafika AI, Tziomalos K, et al. Pleiotropic effects of statins: clinical evidence. Curr Pharm Des 2009; 15:479-489.
11. Katsiki N, Tziomalos K, Chatzizisis Y, et al. Effect of HMG-CoA reductase inhibitors on vascular cell apoptosis: beneficial or detrimental? Atherosclerosis 2010; 211:9-14.
12. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol 2001; 21:1712-1719. (Pubitemid 34219772)
13. Oka M, Fagan KA, Jones PL, McMurtry IF. Therapeutic potential of RhoA/Rho kinase inhibitors in pulmonary hypertension. Br J Pharmacol 2008; 155:444-454.
14. Xing XQ, Gan Y, Wu SJ, et al. Statins may ameliorate pulmonary hypertension via RhoA/Rho-kinase signaling pathway. Med Hypotheses 2007; 68:1108-1113. (Pubitemid 46274033)
15. Heresi GA, Aytekin M, Newman J, et al. Plasma levels of high-density lipoprotein cholesterol and outcomes in pulmonary arterial hypertension. Am J Respir Crit Care Med 2010; 182:661-668.
16. Katsiki N, Athyros VG, Mikhailidis DP. New developments in the treatment and prevention of vascular disease: part 1. Curr Pharm Des 2010; 16:3767-3769.
17. Li M, Li Z, Sun X. Statins suppress MMP2 secretion via inactivation of RhoA/ROCK pathway in pulmonary vascular smooth muscles cells. Eur J Pharmacol 2008; 591:219-223.
18. Chow AK, Cena J, Schulz R. Acute actions and novel targets of matrix metalloproteinases in the heart and vasculature. Br J Pharmacol 2007; 152:189-205. (Pubitemid 47517601)
19. Ikeda T, Nakamura K, Akagi S, et al. Inhibitory effects of simvastatin on platelet-derived growth factor signaling in pulmonary artery smooth muscle cells from patients with idiopathic pulmonary arterial hypertension. J Cardiovasc Pharmacol 2010; 55:39-48. A possible mechanism by which simvastatin could benefit patients with PAH.
20. Li J, Li JJ, He JG, et al. Atorvastatin decreases C-reactive protein-induced inflammatory response in pulmonary artery smooth muscle cells by inhibiting nuclear factor-kappaB pathway. Cardiovasc Ther 2010; 28:8-14. A possible mechanism by which atorvastatin could benefit patients with PAH.
21. Schrier RW, Bansal S. Pulmonary hypertension, right ventricular failure, and kidney: different from left ventricular failure? Clin J Am Soc Nephrol 2008; 3:1232-1237.
22. Jiang X, Han ZY, Wang Y, et al. Hemodynamic variables and clinical features correlated with serum uric acid in patients with pulmonary arterial hypertension. Chin Med J (Engl) 2008; 121:2497-2503.
23. Girgis RE, Li D, Zhan X, et al. Attenuation of chronic hypoxic pulmonary hypertension by simvastatin. Am J Physiol Heart Circ Physiol 2003; 285:H938-H945. (Pubitemid 37048146)
24. Girgis RE, Mozammel S, Champion HC, et al. Regression of chronic hypoxic pulmonary hypertension by simvastatin. Am J Physiol Lung Cell Mol Physiol 2007; 292:L1105-L1110. (Pubitemid 47084854)
25. Taraseviciene-Stewart L, Scerbavicius R, Choe KH, et al. Simvastatin causes endothelial cell apoptosis and attenuates severe pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2006; 291:L668-L676. (Pubitemid 44498478)
26. Hsu HH, Ruan T, Ko WJ, et al. Effects of simvastatin on pulmonary C-fiber sensitivity in rats with monocrotaline-induced pulmonary hypertension. J Heart Lung Transplant 2011; 30:332-340.
27. Liu B, Wang XQ, Yu L, et al. Simvastatin restores down-regulated GATA-6 expression in pulmonary hypertensive rats. Exp Lung Res 2009; 35:411-426.
28. Satoh K, Fukumoto Y, Nakano M, et al. Statin ameliorates hypoxia-induced pulmonary hypertension associated with down-regulated stromal cell-derived factor-1. Cardiovasc Res 2009; 81:226-234.
29. Nishimura T, Faul JL, Berry GJ, et al. Simvastatin attenuates smooth muscle neointimal proliferation and pulmonary hypertension in rats. Am J Respir Crit Care Med 2002; 166:1403-1408. (Pubitemid 35292709)
30. Carlin CM, Peacock AJ, Welsh DJ. Fluvastatin inhibits hypoxic proliferation and p38 MAPK activity in pulmonary artery fibroblasts. Am J Respir Cell Mol Biol 2007; 37:447-456. (Pubitemid 47502720)
31. Nishimura T, Vaszar LT, Faul JL, et al. Simvastatin rescues rats from fatal pulmonary hypertension by inducing apoptosis of neointimal smooth muscle cells. Circulation 2003; 108:1640-1645. (Pubitemid 37187793)
32. Lee JH, Lee DS, Kim EK, et al. Simvastatin inhibits cigarette smoking-induced emphysema and pulmonary hypertension in rat lungs. Am J Respir Crit Care Med 2005; 172:987-993.
33. Souza-Costa DC, Figueiredo-Lopes L, Alves-Filho JC, et al. Protective effects of atorvastatin in rat models of acute pulmonary embolism: involvement of matrix metalloproteinase-9. Crit Care Med 2007; 35:239-245. (Pubitemid 46035701)
34. Gao YF, Zhu XD, Shi DM, et al. The effects of atorvastatin on pulmonary arterial hypertension and expression of p38, p27, and Jab1 in rats. Int J Mol Med 2010; 26:541-547.
35. Xie L, Lin P, Xie H, Xu C. Effects of atorvastatin and losartan on monocrotaline-induced pulmonary artery remodeling in rats. Clin Exp Hypertens 2010; 32:547-554.
36. Laudi S, Trump S, Schmitz V, et al. Serotonin transporter protein in pulmonary hypertensive rats treated with atorvastatin. Am J Physiol Lung Cell Mol Physiol 2007; 293:L630-L638. (Pubitemid 47358825)
37. Rakotoniaina Z, Guerard P, Lirussi F, et al. The protective effect of HMG-CoA reductase inhibitors against monocrotaline-induced pulmonary hypertension in the rat might not be a class effect: comparison of pravastatin and atorvastatin. Naunyn Schmiedebergs Arch Pharmacol 2006; 374:195-206. (Pubitemid 44819252)
38. Ozturk EI, Uma S. Effects of atorvastatin and L-arginine treatments on electrical field stimulation-mediated relaxations in pulmonary arterial rings of monocrotaline-induced pulmonary hypertensive rats. J Cardiovasc Pharmacol 2010; 56:498-505.
39. Maclean MR, Dempsie Y. The serotonin hypothesis of pulmonary hypertension revisited. Adv Exp Med Biol 2010; 661:309-322.
40. Anderson JR, Nawarskas JJ. Pharmacotherapeutic management of pulmonary arterial hypertension. Cardiol Rev 2010; 18:148-162. A useful and recent review.
41. Dewachter L, Dewachter C, Naeije R. New therapies for pulmonary arterial hypertension: an update on current bench to bedside translation. Expert Opin Investig Drugs 2010; 19:469-488. A useful and recent review.
42. Martin KB, Klinger JR, Rounds SI. Pulmonary arterial hypertension: new insights and new hope. Respirology 2006; 11:6-17.
43. Crespo MJ, Quidgley JA. Statins decrease serotonin-induced contractions in coronary arteries of swine in vitro. Pharmacology 2006; 76:141-147. (Pubitemid 43289467)
44. Sjogren B, Hamblin MW, Svenningsson P. Cholesterol depletion reduces serotonin binding and signaling via human 5-HT(7(a)) receptors. Eur J Pharmacol 2006; 552:1-10. (Pubitemid 44648071)
45. Alnaeb ME, Thompson CS, Seifalian AM, et al. Regional differences in the expression of nitric oxide synthase and specific receptors in the vascular tissues of control and diabetic rabbits: a pilot study. In Vivo 2007; 21:1069-1074. (Pubitemid 350286338)
46. McMurtry MS, Bonnet S, Michelakis ED, et al. Statin therapy, alone or with rapamycin, does not reverse monocrotaline pulmonary arterial hypertension: the rapamcyin-atorvastatin-simvastatin study. Am J Physiol Lung Cell Mol Physiol 2007; 293:L933-L940. (Pubitemid 47572241)
47. Guerard P, Rakotoniaina Z, Goirand F, et al. The HMG-CoA reductase inhibitor, pravastatin, prevents the development of monocrotaline-induced pulmonary hypertension in the rat through reduction of endothelial cell apoptosis and overexpression of eNOS. Naunyn Schmiedebergs Arch Pharmacol 2006; 373:401-414. (Pubitemid 44401411)
48. Murata T, Kinoshita K, Hori M, et al. Statin protects endothelial nitric oxide synthase activity in hypoxia-induced pulmonary hypertension. Arterioscler Thromb Vasc Biol 2005; 25:2335-2342. (Pubitemid 41552651)
49. Sun X, Ku DD. Rosuvastatin provides pleiotropic protection against pulmonary hypertension, right ventricular hypertrophy, and coronary endothelial dysfunction in rats. Am J Physiol Heart Circ Physiol 2008; 294:H801-H809. (Pubitemid 351253291)
50. DeMarco VG, Habibi J, Whaley-Connell AT, et al. Rosuvastatin ameliorates the development of pulmonary arterial hypertension in the transgenic (mRen2)27 rat. Am J Physiol Heart Circ Physiol 2009; 297:H1128-H1139.
51. Laudi S, Steudel W, Jonscher K, et al. Comparison of lung proteome profiles in two rodent models of pulmonary arterial hypertension. Proteomics 2007; 7:2469-2478. (Pubitemid 47134539)
52. Wright JL, Zhou S, Preobrazhenska O, et al. Statin reverses smoke-induced pulmonary hypertension and prevents emphysema but not airway remodeling. Am J Respir Crit Care Med 2011; 183:50-58.
53. Kao PN. Simvastatin treatment of pulmonary hypertension: an observational case series. Chest 2005; 127:1446-1452. (Pubitemid 46224314)
54. Wilkins MR, Ali O, Bradlow W, et al. Simvastatin as a Treatment for Pulmonary Hypertension Trial. Am J Respir Crit Care Med 2010; 181:1106-1113. One of the statin trials in PAH.
55. Barreto AC, Maeda NY, Soares RP, et al. Rosuvastatin and vascular dysfunction markers in pulmonary arterial hypertension: a placebo-controlled study. Braz J Med Biol Res 2008; 41:657-663.
56. Lee TM, Chen CC, Shen HN, Chang NC. Effects of pravastatin on functional capacity in patients with chronic obstructive pulmonary disease and pulmonary hypertension. Clin Sci (Lond) 2009; 116:497-505. One of the statin trials in PAH.
57. Battistini B, D'Orleans-Juste P, Sirois P. Endothelins: circulating plasma levels and presence in other biologic fluids. Lab Invest 1993; 68:600-628. (Pubitemid 23202790)